Broad- and narrow-sense validity performance of three polygenic risk score methods for prostate cancer risk assessment

被引:7
作者
Yu, Hongjie [1 ]
Shi, Zhuqing [1 ]
Lin, Xiaoling [2 ]
Bao, Quanwa [3 ]
Jia, Haifei [2 ]
Wei, Jun [1 ]
Helfand, Brian T. [1 ]
Zheng, Siqun. L. [1 ]
Duggan, David [4 ]
Lu, Daru [3 ]
Mo, Zengnan [5 ]
Xu, Jianfeng [1 ,2 ]
机构
[1] NorthShore Univ HealthSyst, Program Personalized Canc Care, 1001 Univ Pl, Evanston, IL 60201 USA
[2] Fudan Univ, Huashan Hosp, Fudan Inst Urol, Shanghai, Peoples R China
[3] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China
[4] City Hope Natl Med Ctr, Translat Genom Res Inst, Phoenix, AZ USA
[5] Guangxi Med Univ, Ctr Genom & Personalized Med, Nanning, Guangxi Zhuang, Peoples R China
关键词
clinical validity; genetic risk score; prostate cancer; GENOME-WIDE ASSOCIATION; MEN; PREDICTION; VARIANTS; BIOPSY;
D O I
10.1002/pros.23920
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Several polygenic risk score (PRS) methods are available for measuring the cumulative effect of multiple risk-associated single nucleotide polymorphisms (SNPs). Their performance in predicting risk at the individual level has not been well studied. Methods We compared the performance of three PRS methods for prostate cancer risk assessment in a clinical trial cohort, including genetic risk score (GRS), pruning and thresholding (P + T), and linkage disequilibrium prediction (LDpred). Performance was evaluated for score deciles (broad-sense validity) and score values (narrow-sense validity). Results A training process was required to identify the best P + T model (397 SNPs) and LDpred model (3 011 362 SNPs). In contrast, GRS was directly calculated based on 110 established risk-associated SNPs. For broad-sense validity in the testing population, higher deciles were significantly associated with higher observed risk;P(trend)was 7.40 x 10(-11), 7.64 x 10(-13), and 7.51 x 10(-10)for GRS, P + T, and LDpred, respectively. For narrow-sense validity, the calibration slope (1 is best) was 1.03, 0.77, and 0.87, and mean bias score (0 is best) was 0.09, 0.21, and 0.10 for GRS, P + T, and LDpred, respectively. Conclusions The performance of GRS was better than P + T and LDpred. Fewer and well-established SNPs of GRS also make it more feasible and interpretable for genetic testing at the individual level.
引用
收藏
页码:83 / 87
页数:5
相关论文
共 50 条
[21]   Gastric Cancer Risk Prediction Using an Epidemiological Risk Assessment Model and Polygenic Risk Score [J].
Park, Boyoung ;
Yang, Sarah ;
Lee, Jeonghee ;
Choi, Il Ju ;
Kim, Young-Il ;
Kim, Jeongseon .
CANCERS, 2021, 13 (04) :1-13
[22]   Predictive value of polygenic risk score for prostate cancer incidence and prognosis in the Han Chinese [J].
Hung, Sheng-Chun ;
Chang, Li-Wen ;
Hsiao, Tzu-Hung ;
Wei, Chia-Yi ;
Wang, Shian-Shiang ;
Li, Jian-Ri ;
Chen, I-Chieh .
SCIENTIFIC REPORTS, 2024, 14 (01)
[23]   Assessment of polygenic risk score performance in East Asian populations for ten common diseases [J].
Jung, Hae-Un ;
Jung, Hyein ;
Baek, Eun Ju ;
Kang, Ji-One ;
Kwon, Shin Young ;
You, Jaeyoon ;
Lim, Ji Eun ;
Oh, Bermseok .
COMMUNICATIONS BIOLOGY, 2025, 8 (01)
[24]   Polygenic Risk Score Improves Prostate Cancer Risk Prediction: Results from the Stockholm-1 Cohort Study [J].
Aly, Markus ;
Wiklund, Fredrik ;
Xu, Jianfeng ;
Isaacs, William B. ;
Eklund, Martin ;
D'Amato, Mauro ;
Adolfsson, Jan ;
Gronberg, Henrik .
EUROPEAN UROLOGY, 2011, 60 (01) :21-28
[25]   Association of Prostate-Specific Antigen Levels with Prostate Cancer Risk in a Multiethnic Population: Stability Over Time and Comparison with Polygenic Risk Score [J].
Chou, Alisha ;
Darst, Burcu F. ;
Wilkens, Lynne R. ;
Le Marchand, Loic ;
Lilja, Hans ;
V. Conti, David V. ;
Haiman, Christopher A. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2022, 31 (12) :2199-2207
[26]   A Novel Risk Score (P-score) Based on a Three-Gene Signature, for Estimating the Risk of Prostate Cancer-Specific Mortality [J].
Soderdahl, Fabian ;
Xu, Li-Di ;
Bring, Johan ;
Haggman, Michael .
RESEARCH AND REPORTS IN UROLOGY, 2022, 14 :203-217
[27]   Performance of Three Inherited Risk Measures for Predicting Prostate Cancer Incidence and Mortality: A Population-based Prospective Analysis [J].
Shi, Zhuqing ;
Platz, Elizabeth A. ;
Wei, Jun ;
Na, Rong ;
Fantus, Richard J. ;
Wang, Chi-Hsiung ;
Eggener, Scott E. ;
Hulick, Peter J. ;
Duggan, David ;
Zheng, S. Lilly ;
Cooney, Kathleen A. ;
Isaacs, William B. ;
Helfand, Brian T. ;
Xu, Jianfeng .
EUROPEAN UROLOGY, 2021, 79 (03) :419-426
[28]   Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients [J].
Xu, Jianfeng ;
Isaacs, William B. ;
Mamawala, Mufaddal ;
Shi, Zhuqing ;
Landis, Patricia ;
Petkewicz, Jacqueline ;
Wei, Jun ;
Wang, Chi-Hsiung ;
Resurreccion, W. Kyle ;
Na, Rong ;
Bhanji, Yasin ;
Novakovic, Kristian ;
Walsh, Patrick C. ;
Zheng, S. Lilly ;
Helfand, Brian T. ;
Pavlovich, Christian P. .
PROSTATE, 2021, 81 (10) :703-709
[29]   The Quantitative Gleason Score Improves Prostate Cancer Risk Assessment [J].
Reese, Adam C. ;
Cowan, Janet E. ;
Brajtbord, Jonathan S. ;
Harris, Catherine R. ;
Carroll, Peter R. ;
Cooperberg, Matthew R. .
CANCER, 2012, 118 (24) :6046-6054
[30]   An early-onset specific polygenic risk score optimizes age-based risk estimate and stratification of prostate cancer: population-based cohort study [J].
Cheng, Yifei ;
Wu, Lang ;
Xin, Junyi ;
Ben, Shuai ;
Chen, Silu ;
Li, Huiqin ;
Zhao, Lingyan ;
Wang, Meilin ;
Cheng, Gong ;
Du, Mulong .
JOURNAL OF TRANSLATIONAL MEDICINE, 2024, 22 (01)